Menu
2025 Session

Budget Amendments - HB1600 (Conference Report)

View Budget Item
View Budget Item amendments

Reduce Cost of Insulin

Item 101 #6c

Item 101 #6c

First Year - FY2025 Second Year - FY2026
Commerce and Trade
Economic Development Incentive Payments FY2025 $3,000,000 FY2026 $0 GF

Language
Page 104, line 21, strike "$100,022,331" and insert "$103,022,331".

Page 108, after line 9, insert:

"V. Out of this appropriation, $3,000,000 the first year from the general fund is provided to the Virginia Economic Development Partnership Authority to support a non-profit operating a pharmaceutical manufacturing facility in developing a fast-acting insulin. Prior to any funds being disbursed, the authority shall enter into a Memorandum of Understanding (MOU) with a non-profit organization and the company shall demonstrate a match of non-state funds equal to the amount provided in this paragraph. The MOU shall include: (i) a commitment by the company to produce a fast-acting biosimilar insulin at a price of not more than $30 per vial and not more than $55 for five pre-filled insulin pens; (ii) provisions related to the repayment of the funds provided in this paragraph should the company fail to produce and distribute a low-cost insulin; and (iii) annual reporting by the company to the uthority on the development of the fast-acting biosimilar insulin. At the conclusion of the project, the company shall be required to report to the authority on the: (i) jobs created as a result of the investment; (ii) estimated savings to residents of the Commonwealth from purchase of low-cost insulin; and, (iii) estimated potential savings to the Commonwealth as a self-insured employer from the availability of affordable insulin manufactured at a non-profit facility in Virginia.  Any funding remaining at the end of the fiscal year 2025 shall be carried forward into the next fiscal year for the purposes described in this paragraph V."



Explanation

(This amendment provides $3.0 million from the general fund the first year to invest in the development of a fast-acting insulin to reduce the cost of this drug for consumers to no more than $30 per vial.)